Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2017
- Pages: 1436
- Published: December 2017
- Report Code: GMDHC10029IDB
Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2017’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects
The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
Aadi Bioscience Inc
AbbVie Inc
Actuate Therapeutics Inc
Adaptimmune Therapeutics Plc
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Advenchen Laboratories LLC
Affitech A/S
Alethia Biotherapeutics Inc
Alkermes Plc
Altor BioScience Corp
Ambrx Inc
Amgen Inc
Ampio Pharmaceuticals Inc
Apac Biotech Pvt Ltd
Apcure SAS
APEIRON Biologics AG
Aphios Corp
arGEN-X BV
Argos Therapeutics Inc
ARMO Biosciences Inc
ArQule Inc
Arrowhead Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bio-Cancer Treatment International Ltd
Biocad
Biohaven Pharmaceutical Holding Company Ltd
Bionomics Ltd
Bionovis SA
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellular Biomedicine Group Inc
Celyad SA
Checkpoint Therapeutics Inc
Chipscreen Biosciences Ltd
Cleave Biosciences Inc
Cleveland BioLabs Inc
Clovis Oncology Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Corvus Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Eli Lilly and Co
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Glycotope GmbH
Hemispherx Biopharma Inc
HitGen LTD
Horizon Pharma Plc
Hutchison MediPharma Ltd
Ignyta Inc
Ildong Pharmaceutical Co Ltd
Immune Design Corp
Immune Pharmaceuticals Inc
Immunicum AB
ImmunoFrontier Inc
ImmunoGen Inc
Immunomedics Inc
Immunomet Therapeutics Inc
Incyte Corp
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
Johnson & Johnson
KAHR medical Ltd
Karyopharm Therapeutics Inc
KineMed Inc
Kite Pharma Inc
Konruns Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Lidds AB
Lycera Corp
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Mantis Therapeutics BV
MaxiVAX SA
MedImmune LLC
Medinet Co Ltd
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Moderna Therapeutics Inc
Molecular Partners AG
Moleculin Biotech Inc
Mologen AG
Monopar Therapeutics LLC
Mycenax Biotech Inc
NantKwest Inc
NBE-Therapeutics AG
Nektar Therapeutics
NewLink Genetics Corp
Novartis AG
NovaTarg Therapeutics Inc
Omeros Corp
OncBioMune Pharmaceuticals Inc
Oncobiologics Inc
Oncolys BioPharma Inc
OncoMax
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Peloton Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pharmicell Co Ltd
Pivotal BioSciences Inc
Plexxikon Inc
PsiOxus Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Sanofi
Selvita SA
Sevion Therapeutics Inc
Shionogi & Co Ltd
Sillajen Biotherapeutics
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Systimmune Inc
Taiwan Liposome Company Ltd
Taris Biomedical LLC
TC BioPharm Ltd
Tesaro Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
TRACON Pharmaceuticals Inc
TVAX Biomedical Inc
Tyrogenex Inc
UroGen Pharmaceuticals Ltd
Vaccibody AS
Vascular Biogenics Ltd
Vault Pharma Inc
Vaxeal Holding SA
ViiV Healthcare UK Ltd
Vyriad Inc
X4 Pharmaceuticals Inc
Xspray Pharma AB
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.